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.1. Introduction
VitaminD is a steroid hormonemainly knownas regulator of calcium/
phosphate homeostasis. The active form of the hormone, calcitriol, is pro-
duced beginning from a precursor located on the skin, upon UVB rays
exposure; the whole Vitamin D amount also depends on dietary intake
and intestinal absorption.
Strong evidences have shown vitamin D biology to have broad areas
of signiﬁcance in immunological processes and inﬂammation [1,2,3].
Thus, the role of the hormone in autoimmune disorders has been
greatly examined [4,5].
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linked to Vitamin D deﬁciency [6,7].
Systemic Sclerosis (SSc) is a connective tissue disorder characterized
by skin ﬁbrosis, internal organ involvement and ﬁbroproliferative
vasculopathy. Skin ﬁbrosis is the hallmark of the disease and lung and
gastrointestinal tract represent the most affected organs involved [8].
Both malabsorption and skin thickening might cause vitamin D
deﬁciency [9]; thereby, it is an intriguing question, still unanswered,
whether hypovitaminosis D has a role in the pathogenesis of SSc or it
is a consequence of clinical features.
Manifold data [9–13] have been provided about the association
between low Vitamin D serum levels and clinical features of disease,
but few evidences were found to be concordant. Since understanding
the pathogenesis implies advances in therapeutic strategies, it is a
need to draw conclusions about the role, true or fake, of the hormone,
in promoting the onset of SSc.
In this paper, previous studies assessing hypovitaminosis D in system-
ic sclerosis have been reviewed and the relation with pathogenesis and
clinical features has been examined.2. Methods
We searched the PubMed and the Cochrane Library electronic data-
bases for articles with no limits for language, year, type and status of
publication, using the keywords “systemic sclerosis” and “vitamin D”.
Data was collected by two independent reviewers. Quality of each
study was assessed by two reviewers working independently. Eligi-
bility criteria were: reporting measurement of Vitamin D serum
levels in all participants and evaluating of adult onset SSc individuals
as patients group. Exclusion criteria were: evaluation of autoimmune
diseases other than SSc, lack of vitamin D measurement, prospective
and interventional studies evaluating vitamin D supplementation
related to SSc development risk or to disease course modifying. No re-
strictions for gender and ethnic/geographical variables of participants
were imposed. The reference lists of the relevant articles were scanned
for additional studies. Two reviews and four letters were included. In
all the studies reviewed deﬁciency and insufﬁciency of vitamin D
were deﬁned as serum hormone levels below 30 and 10 ng/ml, re-
spectively. In this review, both deﬁciency and insufﬁciencywere gener-
ally indicated as hypovitaminosis. In all the studies included in this
review, differences in means and standard deviations were used to
compare vitamin D levels among participants; the association between
hypovitaminosis D and clinical features was evaluated via appropriate
statistical analysis.3. Results
A total of 115 articles were obtained from the databases. 86 articles
were discarded because after reviewing the abstract they were found
not including SSc patients groups or vitamin D serum levels determina-
tion; 2 were not available online and 1 was a duplicate due to an errata
corrige. 26 articles remained and 9 were excluded after reviewing full
text, because they did not meet the inclusion criteria as described
above. A ﬁnal total of 17 articles were selected based on the eligibility
criteria. An additional 5 studies that met the inclusion criteria were ob-
tained by checking the references of the relevant articles.
All were cross-sectional, small sample size studies, except that per-
formed byArnson et al. Two studies includedOsteoarthritis andRheuma-
toid Arthritis affected individuals as control group. Two independent
reviewers assessed the main risk of bias for all the studies included,
which mainly was due to lack of demographic and clinic information
and drug interferences, consequently resulting in mendacious values of
vitamin D.
All ﬁndings reported are summarized in Table 1.4. Discussion
Among clinical features and laboratory measurement, Bone Mineral
Density (BMD) and skin ﬁbrosis were more frequently investigated in
association with low vitamin D levels.
Auto-antibodies proﬁle, including anti-topoisomerase antibody I
(Scl 70), anti-nuclear antibodies (ANA) and anti-centromere antibodies
(ACA), has been reported to be associated with low hormone levels by
Vacca et al., but following reports in the same ﬁndings failed [9–11];
[13–17]. Lately, Carmel et al. reported no correlation between anti-
vitamin D antibodies and some clinical features [18]. Acute-phase reac-
tant including C-Reactive Protein (CRP) and Erythrocyte Sedimentation
Rate (ESR) were extensively investigated in some studies reviewed
[11–14]. Serum calcium, phosphate and bone turnover metabolism
were mostly measured in those papers having BMD or parathyroid
hormone (PTH) determination in their study protocol [19–21].
To note that Braun-Moscovici [22] ﬁrstly found an association be-
tween hypovitaminosis D and PTH levels whereas in 2011 [23] reported
opposite evidences.
Controversial ﬁndings about the association between Body Mass
Index (BMI) and hypovitaminosis D was reported [11,16,17,24,25].
Not surprisingly, the associationwith pulmonary and gastrointestinal
tests have been greatly sought, but inconsistent data have been provided
[9,11,13,14,16];[24–26].
Findings of an association between vitamin D deﬁciency/insufﬁciency
and clinical features of disease are greatly controversial, albeit intriguing.
Since SSc is a relatively rare disease, small sample size, in all the studies
considered, consequently makes the results quite inconclusive. Although
Arnson et al. enrolled the most large patients group, demographic and
clinical data was incomplete [10]. Other limitations due to mixed partici-
pants (Italian and French) were presented by Vacca et al. [14].
Many efforts have beenmade tounderstand the role of lowhormone
levels in the pathogenesis of the disease, as well as its relation with skin
ﬁbrosis and clinical features. Skin ﬁbrosis is the mainly investigated
aspect in this ﬁeld; a sound reason why investigating lies in the patho-
genesis of disease.
Corrado et al. [9] and Arnson et al. [10] found an inverse relation
between skin ﬁbrosis and low vitamin D serum levels; however, the
former failed when seeking an association of Hypovitaminosis D with
the extent of skin ﬁbrosis [10]. Immune system dysfunction and extra-
cellular matrix deposition are the main pathogenetic steps underlying
the hallmarks of disease. Few studies have looked into this question,
concluding both matrix deposition and immune dysfunction might be
vitamin D-related [25,27–29].
Vitamin D is considered as a natural modulator and regulator of na-
tive and type 1 adaptative immune system [6,31], controlling neutro-
phils activity and inﬂammatory response [2]. It has an antiﬁbrotic
effect on ﬁbroblasts, consequently inhibitingsynthesis and deposition
of extracellular matrix [5]. Vitamin D receptor (VDR) signalling is partly
responsible for immunoregulating effects on both innate and adaptative
immune responses, due to the expression of VDR on the surface of anti-
gen presenting cell (APC), natural killer cells, aswell as activated B and T
lymphocytes [32,33].
Immunomodulating effects of Vitamin D can be summarized by
these few sentences: production of auto- antibodies; inhibition of Th1
cytokine (IL1,TNFα, IFNγ); reduction of proinﬂammatory cytokines
(IL6 and IL17); up- regulation of anti-inﬂammatory cytokines (IL4–10)
[34]. Concisely, vitamin D acts skewing T cells to Th2 polarization [5,
28]; a Th2cytokine-mediatedmechanism could be the native promoting
factor responsible for TGFβ activity and proﬁbrotic effects [9,10,28].
4.1. VDR, autoimmunity and infections
Some authors [27] suggested proﬁbrotic direct effect on ﬁbroblast
to be VDR dependent; impaired VDR might lead to hyperactive TGFβ
signalling and abnormal ﬁbroblast activation [27]. It might have been
Table 1
Studies investigated the potential association 437 between hypovitaminosis D and serum 438 markers and/or clinical characteristics.
Low vitamin D serum levels (b30 ng/ml)
Serum markers Acute phase reactants CRP + Caramaschi et al. (2010)a, Vacca et al. (2009),
− Atteritano et al. (2013)
ESR + Caramaschi et al. (2010)a, Vacca et al. (2009),
− Zhang et al. (2015) and Atteritano et al. (2013)
Rheumatoid factor + Arnson et al. (2011)
−
C3 + Zhang et al. (2015)
−
Autoantibodies (ANA, SCL70.) + Vacca et al. (2009), Ibn Yacoub et al. (2012),
− Corrado et al. (2015)b, Caramaschi et al. (2010)a, Gambichler et al. (2011),
Zhang et al. (2015), Arnson et al. (2011), Belloli et al. (2011) and Carmel et al. ( 2015)
Clinical
characteristics
Skin ﬁbrosis (mRSS) + Corrado et al. (2015)b,Arnson et al. (2011),
− Gambichler et al. (2011), Zhang et al. (2015), Calzolari et al. (2009), Kilic et al. (2013),
Belloli et al. (2011) and Caramaschi et al. (2010)a
Cutaneous subtype (limited/diffuse) + Vacca et al. (2009), Corrado et al. (2015)b,
− Kilic et al. (2013), Belloli et al. (2011), Calzolari et al. (2009),
Caramaschi et al. (2010)a, Arnson et al. (2011) and Gambichler et al. (2011)
NVC + Caramaschi et al. (2010)a
−
Disease duration + Caramaschi et al. (2010)a,
− Vacca et al. (2009), Corrado et al. (2015)b, Kilic et al. (2013), Belloli et al. (2011),
Calzolari et al. (2009) and Atteritano et al. (2013)
Disease activity (EDAS) + Vacca et al. (2009),
− Caramaschi et al. (2010)a and Braun-Moscovici et al. (2011)
Disease severity (Medsger's severity score) + Caramaschi et al. (2010)a,
−Vacca et al. (2009), Kilic et al. (2013), Belloli et al. (2011) and Calzolari et al. (2009)
Internal organ involvement Lung DLCO + Caramaschi et al. (2010)a, Arnson et al. (2011), Vacca et al. (2009),
− Zhang et al. (2015) and Corrado et al. (2015)b
PAP + Vacca et al. (2009), Caramaschi et al. (2010)a,
− Corrado et al. (2015)b, Zhang et al. (2015) and Rios et al. (2010)
Imaging techniques + Caramaschi et al. (2010)a, Vacca et al. (2009),
− Rios et al. (2010), Arnson et al. (2011), Zhang et al. (2015) and Corrado et al. (2015)b
GI SIBO + Corrado et al. (2015)b, Calzolari et al. (2009) and Arnson et al. (2011)
−
Malabsorption + Corrado et al. (2015)b and Kilic et al. (2013)
−
Reﬂux + Corrado et al. (2015)b, Calzolari et al. (2009) and Gambichler et al. (2011)
−
BMI + Zhang et al. (2015),
− Gambichler et al. (2011), Kilic et al. (2013), Belloli et al. (2011), and Calzolari et al. (2009)
Serum calcium and phosphate + Atterritano et al. (2013) and Vacca et al. (2009)
−
BMD/osteoporosis + Atterritano et al. (2013), Carbone et al. (1999), Kamen et al. (2006),
Morgan et al. (2000), Caramaschi et al. (2010)a, Braun-Moscovici et al. (2008),
Ibn Yacoub et al. (2012),
− Rios et al. (2010), and Corrado et al. (2015)b
PTH + Atterritano et al. (2013), Hollis et al. (2005),
− Braun-Moscovici et al. (2008), Vacca et al. (2009), and Braun-Moscovici et al. (2011)
+: Authors found an association between hypovitaminosis D and clinical or laboratory variables;−: Authors did not ﬁnd an association between hypovitaminosis D and clinical or lab-
oratory variables. CRP: C Reactive Protein; ESR: Erythrocyte Sedimentation Rate; mRSS: modiﬁed Rodnan Skin Score; NVC: Nailfold videocapillaroscopy; EDAS: European Disease Activity
Score; DLCO: Diffusion Lung CO; PAP: Pulmonary Alveolar Proteinosis; GI: Gastro Intestinal; SIBO: Small Intestinal Bacterial Overgrowth; BMI: Body Mass Index; BMD: Bone Mineral
Density; PTH: Parathyroid Hormone.
a These Authors compared clinical and laboratory variables between a group of SS patients with Vitamin D deﬁciency and a group of SS patients with Vitamin D insufﬁciency.
b These Authors investigated association between Vitamin D and clinical or laboratory variables in three groups: controls, limited cutaneous subtype of SS and diffused cutaneous
subtype of SS.
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complex comprises retinoid acid receptor (RXR) and VDR responsive
elements (VDREs); the complex vitamin D/VDR/VDRE is known to con-
trol the expression of over two hundreds genes [35]. Szdoray et al. [4] in
2008 reported no correlation between VDR polymorphism and the
frequency of the development of Diabetes Mellitus (DM), Systemic
Erythematosus Lupus (SLE), Rheumatoid Arthritis (RA), but following
studies reported opposite data [6], thereby further investigations might
be reasonable. Owing to its key role in innate response, VDR dysfunction
makes prone to chronic autoimmune disorders infections- related [36]; it
might be sound to evaluate the association between infectious agent
seroprevalence and VDR polymorphisms. An argued list of viruses and
bacteria that may be reasonable to seek in association with VDR poly-
morphisms and SSc clinical features is provided below.About endothelial cell dysfunction, which is the ﬁrst step toward
vasculitis in SSc, it has been suggested the role of viruses and bacteria
in inducing injury [37,38]. Self-reactive antibodies against endothelial
cells might represent an example for molecular mimicry mechanism,
which typically occurs in such an autoimmune disease and explains
pathogenicity of antibodies direct against viruses and bacteria [39].
4.2. Impact of ethnic, geographical and cultural variables on vitamin D
cutaneous absorption
All the papers reviewed were performed in both sunny environment
and high latitude countries. It's of some importance to note that control
groups in such studies reviewed, including north-European individuals
as well asMediterranean ones, often showed vitamin D deﬁciency [9,11].
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showing average values to be signiﬁcantly lower in SSc patients compared
to controls throughout the year [40]. Summer levels were, as expected,
lower than other seasons.
Differences among ethnic groups appear to be of relevant impact
when referred to the Afroamerican population. Dark-skinned individuals
probably developed sun protection strategies due tomigration from low
to high sun environments [41].
Cultural differences in many countries might inﬂuence vitamin D
skin absorption due to traditions and habits, as dress code. One paper
suggested a risk of hypovitaminosis D in ethnic isolates but reported
no differences among three ethnic groups in Israeli [41].4.3. Outlooks
Twomain vitamin D-based therapeutic approaches for autoimmune
disorders are considered, which are supplementary intake and vitamin
D analogues. About supplementary intake many data suggests vitamin
D supplementation not to protect against deﬁciency [14,42,43] in SSc
patients; however, it remains harmless and inexpensive to administer
it.
Vitamin D analogues act as suppressor of cytokine signalling, includ-
ing TGFβ. Major efforts have been done tominimize the effect on calcium
metabolism and maximize the effect of immune modulation in these
molecules. Albeit interesting, all the results provided in this ﬁeld are
rather far from an application on clinical practice [6,30–45].4.4. Low vitamin D level, infections and Systemic Sclerosis
There is a triangular link between infections, autoimmunity and
environment [6]. Low vitamin D serum levels are an increasingly de-
scribed phenomenon worldwide, at least over the last 10–15 years [5,
46]. Waterhouse et al. in 2009 subordinated low vitamin D levels in au-
toimmunity to VDRdysfunction and down regulation [36]; then, Pender
et al. [47] suggested the hormone to represent a major environmental-
linked factor promoting Epstein Barr virus (EBV)-induced autoimmune
diseases. Generally, many infections are known to trigger autoimmune
rheumatic disorders, including RA, SLE and Sjogren Syndrome. Joint in-
volvement in SLE patients has been reported to correlate with the
presence of high titers of EBV antibodies [48]. About Parvovirus B19, a
possible role of infection in the evolution of SSc has been suggested,
reporting B19 viremia or B19 presence in bone marrow, without
viremia; the latter evidence gave the hint to hypothesize that bone
marrowmay represent a reservoir fromwhich the virus spread to target
tissues [49]. A case report of SSc following human Cytomegalovirus
(HCMV) infection in 2002 has been described [50]; moreover, a cross-
reaction of the UL70 protein of HCMV and Scl 70, which are characteris-
tic of diffuse SSc, has been suggested [51]. Helicobacter Pylori (HP) has
been detected in very high percentage of SSc patients [52,53]. Bilgin
et al. [37] in 2015 reported higher prevalence of HP, CMV, EBV, and par-
vovirus B19 in 30 patients with SSc compared with healthy controls.
Unfortunately, no data is available about the association between
Vitamin D deﬁciency/insufﬁciency and increased seroprevalence of
viruses and bacteria.5. Conclusions
Although many efforts have been done, the relation between low
vitamin D and SSc remains unclear. Environment, autoimmunity and
infections are a cross-linked triad greatly unknown. To arrange the hor-
mone in its right place throughout this triad, further investigations
might evaluate the association of VDR genotype and past/current infec-
tions markers with SSc clinical features.References
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